Comparison of Long-term Survival and Toxicity of Simultaneous Integrated Boost Vs Conventional Fractionation with Intensity-modulated Radiotherapy for the Treatment of Nasopharyngeal Carcinoma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 Apr 22

PMID 27099518

Citations 7

Authors

Hengmin Tao

Yumei Wei

Wei Huang

Xiujuan Gai

Baosheng Li

Affiliations

Soon will be listed here.

Abstract

Aim: In recent years, the intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) and intensity-modulated radiotherapy with conventional fractionation (IMRT-CF) have been involved in the treatment of nasopharyngeal carcinoma (NPC). However, the potential clinical effects and toxicities are still controversial.

Methods: Here, 107 patients with biopsy-proven locally advanced NPC between March 2004 and January 2011 were enrolled in the retrospective study. Among them, 54 patients received IMRT-SIB, and 53 patients received IMRT-CF. Subsequently, overall survival (OS), 5-year progression-free survival (PFS), 5-year locoregional recurrence-free survival (LRFS), and relevant toxicities were analyzed.

Results: In the present study, all patients completed the treatment, and the overall median follow-up time was 80 months (range: 8-126 months). The 5-year OS analysis revealed no significant difference between the IMRT-SIB and IMRT-CF groups (80.9% vs 80.5%, P=0.568). In addition, there were also no significant between-group differences in 5-year PFS (73.3% vs 74.4%, P=0.773) and 5-year LRFS (88.1% vs 90.8%, P=0.903). Notably, the dose to critical organs (spinal cord, brainstem, and parotid gland) in patients treated by IMRT-CF was significantly lower than that in patients treated by IMRT-SIB (all P<0.05).

Conclusion: Both IMRT-SIB and IMRT-CF techniques are effective in treating locally advanced NPC, with similar OS, PFS, and LRFS. However, IMRT-CF has more advantages than IMRT-SIB in protecting spinal cord, brainstem, and parotid gland from acute and late toxicities, such as xerostomia. Further prospective study is warranted to confirm our findings.

Citing Articles

Research landscape of radiotherapy for nasopharyngeal carcinoma from 1959 to 2022: A bibliometric analysis.

Huang K, Yang X, Zhang C, Liu X, Hong Y, Cai Q Heliyon. 2024; 10(19):e38475.

PMID: 39397984 PMC: 11470525. DOI: 10.1016/j.heliyon.2024.e38475.

A randomized prospective study comparing acute toxicity, compliance and objective response rate between simultaneous integrated boost and sequential intensity-modulated radiotherapy for locally advanced head and neck cancer.

Grover A, Soni T, Patni N, Singh D, Jakhotia N, Gupta A Radiat Oncol J. 2021; 39(1):15-23.

PMID: 33794570 PMC: 8024186. DOI: 10.3857/roj.2020.01018.

Single-Institute Clinical Experiences Using Whole-Field Simultaneous Integrated Boost (SIB) Intensity-Modulated Radiotherapy (IMRT) and Sequential IMRT in Postoperative Patients With Oral Cavity Cancer (OCC).

Hsieh C, Shueng P, Wang L, Liao L, Lo W, Yeh H Cancer Control. 2020; 27(1):1073274820904702.

PMID: 33047615 PMC: 7791442. DOI: 10.1177/1073274820904702.

Comparison of Radiation-Induced Secondary Malignancy Risk Between Sequential and Simultaneous Integrated Boost for the Treatment of Nasopharyngeal Carcinoma: Intensity-Modulated Radiotherapy versus Volumetric-Modulated Arc Therapy.

Haciislamoglu E, Cinar Y, Eren M, Canyilmaz E, Gurcan F, Serdar L Cancer Manag Res. 2020; 12:2513-2521.

PMID: 32308488 PMC: 7152539. DOI: 10.2147/CMAR.S244901.

Comparative effectiveness of simultaneous integrated boost vs sequential intensity-modulated radiotherapy for oropharyngeal or hypopharyngeal cancer patients: A population-based propensity score-matched analysis.

Kuo Y, Liang J, Wang T, Juan C, Li C, Chien C Medicine (Baltimore). 2019; 98(51):e18474.

PMID: 31861029 PMC: 6940180. DOI: 10.1097/MD.0000000000018474.

References

Dogan N, King S, Emami B, Mohideen N, Mirkovic N, Leybovich L . Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing. Int J Radiat Oncol Biol Phys. 2003; 57(5):1480-91. DOI: 10.1016/s0360-3016(03)01569-4. View

Chen S, Yang S, Liang J, Shiau A, Lin F . Comparative dosimetric study of two strategies of intensity-modulated radiotherapy in nasopharyngeal cancer. Med Dosim. 2005; 30(4):219-27. DOI: 10.1016/j.meddos.2005.07.001. View

Ng W, Lee M, Hung W, Choi C, Lee K, Chan O . Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2010; 79(2):420-8. DOI: 10.1016/j.ijrobp.2009.11.024. View

Kwong D, Sham J, Leung L, Cheng A, Ng W, Kwong P . Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2005; 64(2):374-81. DOI: 10.1016/j.ijrobp.2005.07.968. View

Lee A, Sze W, Au J, Leung S, Leung T, Chua D . Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005; 61(4):1107-16. DOI: 10.1016/j.ijrobp.2004.07.702. View

Lai S, Li W, Chen L, Luo W, Chen Y, Liu L . How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?. Int J Radiat Oncol Biol Phys. 2010; 80(3):661-8. DOI: 10.1016/j.ijrobp.2010.03.024. View

Chen L, Mao Y, Xie F, Liu L, Sun Y, Tian L . The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiother Oncol. 2011; 104(3):331-7. DOI: 10.1016/j.radonc.2011.10.009. View

Butler E, Teh B, Grant 3rd W, Uhl B, Kuppersmith R, CHIU J . Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 1999; 45(1):21-32. DOI: 10.1016/s0360-3016(99)00101-7. View

Marzi S, Pinnaro P, DAlessio D, Strigari L, Bruzzaniti V, Giordano C . Anatomical and dose changes of gross tumour volume and parotid glands for head and neck cancer patients during intensity-modulated radiotherapy: effect on the probability of xerostomia incidence. Clin Oncol (R Coll Radiol). 2011; 24(3):e54-62. DOI: 10.1016/j.clon.2011.11.006. View

10.

Peng G, Wang T, Yang K, Zhang S, Zhang T, Li Q . A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012; 104(3):286-93. DOI: 10.1016/j.radonc.2012.08.013. View

11.

Bakst R, Lee N, Pfister D, Zelefsky M, Hunt M, Kraus D . Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial. Int J Radiat Oncol Biol Phys. 2010; 80(1):148-53. PMC: 2952060. DOI: 10.1016/j.ijrobp.2010.01.026. View

12.

Wong F, Ng A, Lee V, Lui C, Yuen K, Sze W . Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009; 76(1):138-45. DOI: 10.1016/j.ijrobp.2009.01.084. View

13.

Lee N, Harris J, Garden A, Straube W, Glisson B, Xia P . Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009; 27(22):3684-90. PMC: 2720082. DOI: 10.1200/JCO.2008.19.9109. View

14.

Sun X, Su S, Chen C, Han F, Zhao C, Xiao W . Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2013; 110(3):398-403. DOI: 10.1016/j.radonc.2013.10.020. View

15.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

16.

Tao C, Lin L, Zhou G, Tang L, Chen L, Mao Y . Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma. PLoS One. 2014; 9(10):e110765. PMC: 4199726. DOI: 10.1371/journal.pone.0110765. View

17.

Zhang X, Li M, Cao J, Luo J, Xu G, Gao L . Dosimetric variations of target volumes and organs at risk in nasopharyngeal carcinoma intensity-modulated radiotherapy. Br J Radiol. 2011; 85(1016):e506-13. PMC: 3587088. DOI: 10.1259/bjr/20695672. View

18.

Xiao W, Huang S, Han F, Wu S, Lu L, Lin C . Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer. 2011; 117(9):1874-83. DOI: 10.1002/cncr.25754. View